2003 Clinical Development Licensing Small Molecule 
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. This is reflected by our recent share price performance outperforming the index in the past year.”
The Pharma Data
NOVEMBER 5, 2020
Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007.
Expert insights. Personalized for you.
189 
Let's personalize your content